Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐<i>versus</i>‐host disease — a real‐world outcomes analysis
Sameem Abedin(Medical College of Wisconsin), Mehdi Hamadani(Medical College of Wisconsin), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Muhamad Alhaj Moustafa(Jacksonville College), Reena Jayani(Vanderbilt University Medical Center), Shernan G. Holtan(University of Minnesota), Zachariah DeFilipp(Harvard University), Michael R. Grunwald(Levine Cancer Institute), Nahid Rashid(University of Washington), Mary Nauffal(Memorial Sloan Kettering Cancer Center), Candace Butler(Levine Cancer Institute), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Jeanne Palmer(Mayo Clinic), Rizwan Romee(Washington University in St. Louis), Mehrdad Hefazi(Mayo Clinic), Samantha Larson(University of Minnesota Health Maple Grove Clinics), William J. Hogan(Mayo Clinic), Mark A. Schroeder(MACOM (United States)), Joseph Pidala(Moffitt Cancer Center), Farhad Khimani(Moffitt Cancer Center)
Cited by 25
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664